Scientist I
Louisville, Colorado, United States
Multidisciplinary background with a strong focus on CMC analytical development and product characterization. I played a direct role in supporting the advancement of 31 different biopharmaceutical products, spanning pre-clinical through postmarket approval, for 20 innovator client companies.Contributed to method transfer, development, qualification; full product characterization in support of BLA and IND filings; variant and impurity characterization; stability, forced degradation, and process comparability programs; formulation development; structure elucidation.Served as the point of contact for several large, multifaceted programs that required strong organizational and project management abilities. Supported 4 BLA submissions, including 1 approved therapy. Program manager and client point of contact for 1 BLA involving a bioconjugated mAb.Technical Background: HPLC (SEC, HILIC/HIC, RP, IEX) and electrophoresis (CE-SDS, icIEF) separation techniques; mass spectrometry (N- and O-glycan, intact/reduced mass, peptide and disulfide map); biophysical secondary (FUV CD, FTIR), tertiary (NUV CD, DSC), and higher order structure (MALS, SV-AUC, DLS) characterization; bioassay potency (alphascreen), protein quantification (BCA), and limited exposure to cell-based assays; particle characterization (MFI); automation (Biomek 4000); GLP safety (BSL 1-2) and quality practices.